Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lumason® Infusion vs. Bolus Administrations
Details : Lumason is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : NaviFUS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumason is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Sulfur Hexafluoride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : NaviFUS
Deal Size : Inapplicable
Deal Type : Inapplicable